ERR2208938
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.600
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.600
- APICAL_JUNCTION+0.400
- IL6_JAK_STAT3_SIGNALING+0.400
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.400
- ADIPOGENESIS+0.300
- COAGULATION+0.300
- E2F_TARGETS+0.300
- G2M_CHECKPOINT+0.300
- GLYCOLYSIS+0.300
Top 10 suppressed
- ANDROGEN_RESPONSE+0.000
- CHOLESTEROL_HOMEOSTASIS+0.000
- HEDGEHOG_SIGNALING+0.000
- HEME_METABOLISM+0.000
- MITOTIC_SPINDLE+0.000
- P53_PATHWAY+0.000
- PI3K_AKT_MTOR_SIGNALING+0.000
- PROTEIN_SECRETION+0.000
- WNT_BETA_CATENIN_SIGNALING+0.000
- ALLOGRAFT_REJECTION+0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-1106 | Med | Medulloblastoma | 0.871 |
| 2 | BS_M85CXHDV | high-grade glioma | — | 0.859 |
| 3 | TCGA-ZF-AA53-01A-11R-A39I-07 | — | — | 0.852 |
| 4 | 5063882F-6377-4976-BB48-7275D46C44E6 | — | — | 0.851 |
| 5 | AE47BCDE-A2D2-43EF-8EC7-78E4D1817EEE | — | — | 0.844 |
| 6 | 61496AD6-7265-4D58-87CC-4FEE9723106E | — | — | 0.844 |
| 7 | TCGA-BH-A0DZ-01A-11R-A00Z-07 | — | C | 0.844 |
| 8 | MDT-AP-2131 | Med | Medulloblastoma | 0.839 |
| 9 | TCGA-AN-A0AL-01A-11R-A00Z-07 | — | E | 0.839 |
| 10 | D5789BD0-2379-4E96-875F-0C72ED09B96D | — | — | 0.836 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 41 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.600 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.600 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.400 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.400 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.400 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.300 | Inavolisib | — uncovered |
| COAGULATION | 0.300 | Binimetinib | — uncovered |
| E2F_TARGETS | 0.300 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.300 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.300 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.300 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.300 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.300 | Idelalisib | — uncovered |
| MYOGENESIS | 0.300 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.300 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.300 | Cobimetinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.300 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.200 | Temsirolimus | — uncovered |
| APOPTOSIS | 0.200 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |